---
title: "Perspective Therapeutics Earns Buy Rating as Justin Walsh Reaffirms $18 Price Target on Strength of Pb-212 Pipeline and Upcoming Phase III Program"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295953688.md"
description: "JonesTrading analyst Justin Walsh reiterated a Buy rating on Perspective Therapeutics (CATX) with an $18 price target, citing the strength of its Pb-212 pipeline and upcoming Phase III program for SSTR2-positive neuroendocrine tumors. Key drivers include favorable FDA interactions, expanding manufacturing capacity, and strong cash reserves. Additionally, BTIG maintained a Buy rating on CATX with a $14 price target."
datetime: "2026-08-14T15:25:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295953688.md)
  - [en](https://longbridge.com/en/news/295953688.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295953688.md)
generator: "portal-rs"
---

# Perspective Therapeutics Earns Buy Rating as Justin Walsh Reaffirms $18 Price Target on Strength of Pb-212 Pipeline and Upcoming Phase III Program

JonesTrading analyst Justin Walsh has reiterated their bullish stance on CATX stock, giving a Buy rating on August 11.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Justin Walsh has given his Buy rating due to a combination of factors tied to Perspective Therapeutics’ advancing clinical pipeline and platform durability. He views the upcoming Phase III program for Pb-212-VMT-α-NET, guided by new data to be presented at ESMO and supported by favorable FDA interactions, as a key value driver that could yield a differentiated therapy for SSTR2-positive neuroendocrine tumors.

Walsh also highlights the breadth of Pb-212-based programs in FAPα+ solid tumors and MC1R+ melanoma, alongside expanding manufacturing capacity and isotope access that de-risk execution of late-stage trials. Coupled with a strong cash position and the company’s proprietary chelation and pretargeting technologies, he believes CATX is well positioned competitively, supporting his $18 price target and Buy recommendation.

In another report released on August 11, BTIG also maintained a Buy rating on the stock with a $14.00 price target.

### Related Stocks

- [CATX.US](https://longbridge.com/en/quote/CATX.US.md)

## Related News & Research

- [Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results | CATX Stock News](https://longbridge.com/en/news/295446660.md)
- [Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026 | CATX Stock News](https://longbridge.com/en/news/293059465.md)
- [MAR-MAY Sugar #11 SPREAD (SBH27-SBK27) - WALSH PURE SPREADER](https://longbridge.com/en/news/297834886.md)
- [MAR SOYBEANS vs. MAR CORN + MAR WHEAT (SPREAD) - WALSH PURE SPREADER](https://longbridge.com/en/news/297703456.md)
- [DEC WHEAT-CORN SPREAD (ZWZ26-ZCZ26) - WALSH PURE SPREADER](https://longbridge.com/en/news/297242764.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**